Last reviewed · How we verify

EFAPROXIRAL — Competitive Intelligence Brief

EFAPROXIRAL (EFAPROXIRAL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: efaproxiral. Area: Gastroenterology.

discontinued efaproxiral Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

EFAPROXIRAL (EFAPROXIRAL). EFAPROXIRAL works by binding to and stabilizing hemoglobin, reducing the formation of methemoglobin and improving oxygen delivery to tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EFAPROXIRAL TARGET EFAPROXIRAL discontinued efaproxiral

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (efaproxiral class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EFAPROXIRAL — Competitive Intelligence Brief. https://druglandscape.com/ci/efaproxiral. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: